Logo
Loading Weather...

Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating

Business March 6, 2026 0 Views
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating
Source: https://finance.yahoo.com/rss/topstories - Read Original

Discussion (0)

Please log in to post a comment.

No comments yet. Be the first to share your thoughts!